help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by CLANCY, J. P.
Right arrow Articles by BEDWELL, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by CLANCY, J. P.
Right arrow Articles by BEDWELL, D. M.

Am. J. Respir. Crit. Care Med., Volume 163, Number 7, June 2001, 1683-1692

Evidence that Systemic Gentamicin Suppresses Premature Stop Mutations in Patients with Cystic Fibrosis

J. P. CLANCY, ZSUZSA BEBÖK, FADEL RUIZ, CHRIS KING, JULIE JONES, LYNN WALKER, HEATHER GREER, JEONG HONG, LISA WING, MAURIZIO MACALUSO, RAYMOND LYRENE, ERIC J. SORSCHER, and DAVID M. BEDWELL

Departments of Pediatrics, Cell Biology, Medicine, Medical Genetics, Public Health, and Microbiology, University of Alabama at Birmingham; Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham; Children's Hospital, Birmingham, Alabama; and Department of Pediatrics, University of Mississippi, Jackson, Mississippi

Here we report the effects of gentamicin treatment on cystic fibrosis transmembrane regulator (CFTR) production and function in CF airway cells and patients with CF with premature stop mutations. Using immunocytochemical and functional [6-methoxy-N- (3-sulfopropyl) quinolinium (SPQ)-based] techniques, ex vivo exposure of airway cells from stop mutation CF patients led to the identification of surface-localized CFTR in a dose-dependent fashion. Next, five patients with CF with stop mutations and five CF control subjects were treated with parenteral gentamicin for 1 wk, and underwent repeated in vivo measures of CFTR function (nasal potential difference [PD] measurements and sweat chloride [Cl-] testing). During the treatment period, the number of nasal PD readings in the direction of Cl- secretion was increased approximately 3-fold in the stop mutation patient group compared with controls (p < 0.001), and four of five stop mutation patients with CF had at least one reading during gentamicin treatment with a Cl- secretory response of more than -5 mV (hyperpolarized). A response of this magnitude was not seen in any of the CF control subjects (p < 0.05). In an independent series of experiments designed to test the ability of repeat nasal PDs to detect wild-type CFTR function, evidence of Cl- secretion was seen in 88% of control (non-CF) nasal PDs, and 71% were more than -5 mV hyperpolarized. Together, these results suggest that gentamicin treatment can suppress premature stop mutations in airway cells from patients with CF, and produce small increases in CFTR Cl- conductance (as measured by the nasal PD) in vivo.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Du, X. Liu, E. M. Welch, S. Hirawat, S. W. Peltz, and D. M. Bedwell
PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model
PNAS, February 12, 2008; 105(6): 2064 - 2069.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
S. M. Rowe, K. Varga, A. Rab, Z. Bebok, K. Byram, Y. Li, E. J. Sorscher, and J. P. Clancy
Restoration of W1282X CFTR Activity by Enhanced Expression
Am. J. Respir. Cell Mol. Biol., September 1, 2007; 37(3): 347 - 356.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
S. M. Rowe, F. Accurso, and J. P. Clancy
Detection of Cystic Fibrosis Transmembrane Conductance Regulator Activity in Early-Phase Clinical Trials
Proceedings of the ATS, August 1, 2007; 4(4): 387 - 398.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
J. P. Clancy, S. M. Rowe, Z. Bebok, M. L. Aitken, R. Gibson, P. Zeitlin, P. Berclaz, R. Moss, M. R. Knowles, R. A. Oster, et al.
No Detectable Improvements in Cystic Fibrosis Transmembrane Conductance Regulator by Nasal Aminoglycosides in Patients with Cystic Fibrosis with Stop Mutations
Am. J. Respir. Cell Mol. Biol., July 1, 2007; 37(1): 57 - 66.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
S. Hirawat, E. M. Welch, G. L. Elfring, V. J. Northcutt, S. Paushkin, S. Hwang, E. M. Leonard, N. G. Almstead, W. Ju, S. W. Peltz, et al.
Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single- and Multiple-Dose Administration to Healthy Male and Female Adult Volunteers
J. Clin. Pharmacol., April 1, 2007; 47(4): 430 - 444.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
Y. Li, W. Wang, W. Parker, and J. P. Clancy
Adenosine Regulation of Cystic Fibrosis Transmembrane Conductance Regulator through Prostenoids in Airway Epithelia
Am. J. Respir. Cell Mol. Biol., May 1, 2006; 34(5): 600 - 608.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. D. James, S. Raut, G. E. Rivard, M.-C. Poon, M. Warner, S. McKenna, J. Leggo, and D. Lillicrap
Aminoglycoside suppression of nonsense mutations in severe hemophilia
Blood, November 1, 2005; 106(9): 3043 - 3048.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
N. Reiniger, J. K. Ichikawa, and G. B. Pier
Influence of Cystic Fibrosis Transmembrane Conductance Regulator on Gene Expression in Response to Pseudomonas aeruginosa Infection of Human Bronchial Epithelial Cells
Infect. Immun., October 1, 2005; 73(10): 6822 - 6830.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. M. Rowe, S. Miller, and E. J. Sorscher
Cystic Fibrosis
N. Engl. J. Med., May 12, 2005; 352(19): 1992 - 2001.
[Full Text] [PDF]

Home page
 J. Med. Genet.Home page
L S Correa-Cerro, C A Wassif, J S Waye, P A Krakowiak, D Cozma, N R Dobson, S W Levin, G Anadiotis, R D Steiner, M Krajewska-Walasek, et al.
DHCR7 nonsense mutations and characterisation of mRNA nonsense mediated decay in Smith-Lemli-Opitz syndrome
J. Med. Genet., April 1, 2005; 42(4): 350 - 357.
[Full Text] [PDF]

Home page
 J BiochemHome page
M. Arakawa, M. Shiozuka, Y. Nakayama, T. Hara, M. Hamada, S.'i. Kondo, D. Ikeda, Y. Takahashi, R. Sawa, Y. Nonomura, et al.
Negamycin Restores Dystrophin Expression in Skeletal and Cardiac Muscles of mdx Mice
J. Biochem., November 1, 2003; 134(5): 751 - 758.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. L. Gibson, J. L. Burns, and B. W. Ramsey
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 918 - 951.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Wilschanski, Y. Yahav, Y. Yaacov, H. Blau, L. Bentur, J. Rivlin, M. Aviram, T. Bdolah-Abram, Z. Bebok, L. Shushi, et al.
Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis and CFTR Stop Mutations
N. Engl. J. Med., October 9, 2003; 349(15): 1433 - 1441.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. Zabner, P. Karp, M. Seiler, S. L. Phillips, C. J. Mitchell, M. Saavedra, M. Welsh, and A. J. Klingelhutz
Development of cystic fibrosis and noncystic fibrosis airway cell lines
Am J Physiol Lung Cell Mol Physiol, May 1, 2003; 284(5): L844 - L854.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2001
Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 619 - 630.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2001 American Thoracic Society 		  ATS Sleep Tracings Quiz